Stock Watch: Regeneron’s Constellation of Ophthalmic Competition
When One Product Loses Exclusivity, Potentially All Market Shares Can Suffer
Executive Summary
The accepted commercial dynamics of a competitive indication in older patients can be disrupted by new entrants with improved profiles, lower priced biosimilar competition and (soon) Medicare price negotiations.
You may also be interested in...
Stock Watch: Hierarchies Of Drugs Against The Same Target
Rarely does the best-selling product emerge when a newer antibody platform is used to improve on a successful earlier-generation product. Better to play to the platform’s strengths.
Stock Watch: Spanners In The Works For Q4 Results
While the implications of the US Inflation Reduction Act are the focus of the sector’s concern this year, another regulatory development will impact earnings sooner.
High-Dose Eylea’s Improved Durability Could Protect Regeneron’s Market Share
The US firm’s high-dose reformulation of Eylea reduced dosing burden for patients with DME and wet AMD in two pivotal studies and could match Roche’s rival drug.